Get the Stockscreener App
4.2098
0.94%
-0.0302
Vistagen Therapeutics Inc stock is traded at $4.2098, with a volume of 188.73K.
It is down -0.94% in the last 24 hours and up +15.07% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$4.24
Open:
$4.18
24h Volume:
188.73K
Relative Volume:
0.31
Market Cap:
$128.86M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-3.1363
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
+3.70%
1M Performance:
+15.07%
6M Performance:
+76.84%
1Y Performance:
+30.43%
1-Day Range:
$4.10
$4.2963
1-Week Range:
$3.69
$4.6499
52-Week Range:
$1.90
$4.6499
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
4.20 | 130.09M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.55 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
633.42 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.24 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
843.29 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.44 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
Vistagen Therapeutics (VTGN): Examining Valuation After Phase 3 Trial Progress Toward Social Anxiety Treatment Approval - Yahoo Finance
Published on: 2025-11-04 05:24:21 - newser.com
How Vistagen Therapeutics Inc. stock compares to industry benchmarksWeekly Earnings Recap & AI Powered Buy/Sell Recommendations - newser.com
Is Vistagen Therapeutics Inc. stock attractive for income investorsAnalyst Downgrade & Risk Controlled Daily Plans - newser.com
Technical signs of recovery in Vistagen Therapeutics Inc.July 2025 Weekly Recap & Daily Profit Focused Stock Screening - newser.com
Using RSI to spot recovery in Vistagen Therapeutics Inc.July 2025 Sector Moves & Verified Swing Trading Watchlists - newser.com
How to recover losses in Vistagen Therapeutics Inc. stockQuarterly Market Review & Trade Opportunity Analysis - newser.com
VistaGen stock rises after completing Phase 3 trial for anxiety drug By Investing.com - Investing.com Nigeria
VistaGen stock rises after completing Phase 3 trial for anxiety drug - Investing.com Nigeria
What dividend safety score for Vistagen Therapeutics Inc. stockMarket Risk Analysis & Short-Term Trading Alerts - newser.com
Is Vistagen Therapeutics Inc. a candidate for recovery play2025 Earnings Surprises & Low Drawdown Investment Strategies - newser.com
Vistagen Therapeutics Inc. stock trend outlook and recovery pathWeekly Trend Summary & Safe Entry Point Alerts - newser.com
Can Vistagen Therapeutics Inc. stock deliver surprise earnings beat2025 Stock Rankings & Real-Time Volume Triggers - newser.com
Will Vistagen Therapeutics Inc. stock remain a Wall Street favoriteGap Down & Precise Buy Zone Tips - newser.com
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder - Yahoo Finance
Vistagen Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Strategies to average down on Vistagen Therapeutics Inc.Risk Management & Safe Entry Zone Identification - newser.com
Is Vistagen Therapeutics Inc. stock reversal real or fake2025 Retail Activity & Real-Time Volume Triggers - newser.com
Will breakout in Vistagen Therapeutics Inc. lead to full recoveryEarnings Miss & High Return Trade Opportunity Guides - newser.com
Will Vistagen Therapeutics Inc. stock benefit from green energy trends2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Is Vistagen Therapeutics Inc. stock a safe haven assetWeekly Stock Recap & High Accuracy Trade Alerts - newser.com
Will Vistagen Therapeutics Inc. stock gain from strong economy2025 Top Decliners & Fast Gain Swing Trade Alerts - newser.com
Should you hold or exit Vistagen Therapeutics Inc. nowWeekly Risk Summary & Weekly Watchlist for Hot Stocks - newser.com
Using fundamentals and technicals on Vistagen Therapeutics Inc.Earnings Recap Summary & Low Volatility Stock Recommendations - newser.com
Visualizing Vistagen Therapeutics Inc. stock with heatmapsOptions Play & Technical Pattern Alert System - newser.com
Published on: 2025-11-01 04:45:37 - newser.com
Combining machine learning predictions for Vistagen Therapeutics Inc.CEO Change & Reliable Price Action Trade Plans - newser.com
How to escape a deep drawdown in Vistagen Therapeutics Inc.Day Trade & Low Risk Investment Opportunities - newser.com
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):